Drug Trial Radar · NCT01488097
Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency
Last checked: Nov 20, 2026Latest source record: Jul 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Dec 12, 2011
Primary completion
Jun 21, 2017
Study completion Jun 21, 2017
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 8, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an extension study to Study LAL-CL01 (NCT01307098). The primary objective of the study was to evaluate the long-term safety and tolerability of sebelipase alfa in participants with liver dysfunction due to lysosomal acid lipase (LAL) deficiency.
Conditions
- Cholesterol Ester Storage Disease (CESD)
- Lysosomal Acid Lipase Deficiency
- LAL-Deficiency
Interventions
sebelipase alfaDrug
Sebelipase alfa is a recombinant human lysosomal acid lipase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number Of Participants Reporting TEAEs And IARsTime frame: From after first dose administration post-Baseline through EOS during study LAL-CL04
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Eureka, California
Site not named
Sacramento, California
Site not named
San Francisco, California
Site not named
Minneapolis, Minnesota
Site not named
New York, New York
Site not named
Greater Sudbury, Ontario, Canada
Site not named
Prague, Czechia
Site not named
Paris, France
Site not named
Leeds, United Kingdom
Site not named
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.